Aclaris Therapeutics Inc

ACRS · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

ESG Overview

Overall: B (Medium)

E: BS: BG: B

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $3.62 +0.23 (+6.78%)

Market Cap$409M

P/E Ratio—

EPS$—

52W High$4.89

52W Low$1.05

Beta0.89

Data from Finnhub · Updated Mar 10, 2026